Overview
Indications
Plasmodium falciparum (P. falciparum) [see Clinical Studies (14.1)] Coartem Tablets are indicated for treatment of acute, uncomplicated malaria infections due toin patients 2 months of age and older with a bodyweight of 5 kg and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported. Limitations of Use : P. falciparum Coartem Tablets are not approved for patients with severe or complicatedmalaria. Coartem Tablets are not a
Contraindications
When this intervention should not be used
Hypersensitivity [see Adverse Reactions (6.2)] Known hypersensitivity to artemether, lumefantrine, or to any of the excipients of Coartem Tablets. Strong CYP3A4 Inducers [see Warnings and Precautions (5.3), Drug Interactions (7.1), and Clinical Pharmacology (12.3)] Coadministration of strong inducer
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Artemether (substance)
- SNOMED CT
- 420578008
- UMLS CUI
- C0052429
- RxNorm CUI
- 18343
- Labeler
- Novartis Pharmaceuticals Corporation
Clinical Data
This intervention maps to 3 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.